Genesis Research Group’s Post

Lots of exciting insights with oncology manufacturer benchmarking rating on customer experience along with insights on access challenges (e.g., maximizer/accumulator, IRA, AFP) impact on HCPs, field utilization, advances with AI, patient attrition drivers, etc. The study is the most comprehensive of its kind and is bringing the customer voice to strategic decision-making! (see https://lnkd.in/edZbfiUE for more info) #pharma #CustomerExperience #Benchmarking #PURE

In this position paper, Marc argues that #Oncology is the next therapeutic frontier for the application of value-based agreements. As a country and society, we must move towards value-based health - from therapeutics to the provisioning of healthcare services. Thought leaders like Peter have been discussing the societal value and importance of therapeutics for some time. It's now time to put our money where value is created, not destroyed. #NoPatientLeftBehind

The oncology community has embraced pan-tumor products with enthusiasm, signaling that this #precisionmedicine approach is likely to transform the oncology treatment landscape for the next decade. However, pan-tumor strategies prioritize overarching asset strengths vs. the unique considerations potentially required in individual therapy areas, like addressing unique unmet needs, treatment approach and HCP concerns. #Pharma has to find the right balance between pan-tumor and tumor-specific approaches to maximize commercial success for pan-tumor products. #pharma

Unlock oncology success with #IQVIA! The oncology segment is rapidly growing, with projections reaching a staggering $440 billion in revenue by 2028. But here’s the catch: launching successfully within oncology has never been more challenging due to multiple factors converging. Visit us at #ASCO 2024 to meet with IQVIA experts and tackle your launch questions head on: https://bit.ly/3K0cNyY

Struggling to navigate FDA's Project FrontRunner for oncology drug development? Learn how to align your strategies with Project FrontRunner and accelerate the approval process ⏩ Our experts provide valuable insights to help you overcome the complexities and make informed decisions. 💻Watch our webinar now and gain a competitive edge in the evolving landscape of oncology drug development 📩 https://bit.ly/3w3xyGL #FDA #ProjectFrontRunner #Oncology

🔊 Latest article! 💊Patient-centred oncology: transforming drug development As deeper understanding of disease makes the development and commercialisation of oncology drugs more complex, developers are under more pressure than ever to deliver value-based treatments. In this article, Rebecca Goldstein, Senior Principal, Strategic Consulting at Envision Pharma Group, explores anchoring a programme to patient experience as a solution. Click here to read more! 👉 https://bit.ly/3WRG70z #oncology #drugdevelopment #therapeutics

On September 16, 2024, FDA released a guidance draft designed to provide sponsors of cancer drugs who contemplate global clinical development programs with suggestions for strengthening the quality of evidence provided by multiregional trials. There are specific recommendations for planning, designing, conducting, and analyzing MRCTs that will provide data relevant to U.S. cancer patients and U.S. medical practice . Although the guidance offers best practices, it is not legally enforceable unless specific regulatory requirements are cited. #CancerTreatment #OncologyResearch #ClinicalTrials #FDAApproval #DrugDevelopment #GlobalTrials #MRCTs #CancerDrugs #PharmaGuidelines #RegulatoryAffairs

In my view, the importance of the below cannot be emphasized enough. Take a look at the guide for yourself (it's only 2 pages)! #oncologytrials #oncologyresearch #ecoa

Attention Clinical Research Professionals: Upcoming Webinar on FDA's Project FrontRunner! Are you a clinical research professional responsible for designing #oncology registrational trials? The FDA's Project FrontRunner is shaking things up for oncology drug development! Project FrontRunner encourages Sponsors to evaluate promising new oncology therapies in earlier lines of therapy, especially in patients with metastatic disease. This approach could lead to several advantages, including faster access to potentially life-saving treatments, improved evidence for new drugs, and a more efficient drug development process. Join the experts at Veristat for a crucial webinar to learn: ☑ How Project Frontrunner could transform your approach to registrational trials ☑ Strategies to leverage Project Frontrunner and optimize your studies with Veristat's guidance ☑ Practical steps to implement Project Frontrunner for faster development of life-saving treatments Register here: FDA's Project FrontRunner: Optimizing Registrational Trials with Veristat: https://lnkd.in/ePkcWJhE ⭐ ⭐ ⭐ Send a note if I can support your drug development needs. Connect or follow to stay informed of drug development trends. ⭐ ⭐ ⭐ #FDA #drugdevelopment #clinicalresearch #oncology

Ensure you meet regulatory expectations and stand out with a robust Patient-Reported Outcomes (PRO) strategy. Dive into our guide for insights on making your mark in the competitive oncology landscape. Read the guide here: https://hubs.li/Q02ct-j40 #OncologyInnovation #PROStrategy #QualityofLife